Sunday, 20 September 2026European Markets

HOFSETH BIOCARE Stock Over 22% Up In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of HOFSETH BIOCARE (Oslo Børs Benchmark Index_GI: HBC.OL) rose by a staggering 22.4% in 10 sessions from kr2.5 to kr3.06 at 13:38 EST on Thursday, following the last session's upward trend. Oslo Børs Benchmark Index_GI is jumping 0.54% to kr1,249.22, after two consecutive sessions in a row of gains.

HOFSETH BIOCARE's last close was kr2.88, 46.86% below its 52-week high of kr5.42.

About HOFSETH BIOCARE

Hofseth BioCare ASA operates as a consumer and pet health ingredient supplier in Norway and internationally. Its products include Brilliant salmon oil; OmeGo salmon oil for supporting healthy cholesterol and cardiovascular function; ProGo, a salmon protein hydrolysate powder for treatment of irondeficiency anaemia, irritable bowel syndrome (IBS) and sarcopenia; CalGo, a marine calcium powder produced to support cartilage function, joint health, and bone strength; CollaGo, an hair, skin, and nails health treatment and antioxidant; and PetGo, a non-soluble protein. The company distributes its products through distributors, agents, and its own sales force. Hofseth BioCare ASA was founded in 2000 and is headquartered in Ålesund, Norway.

Earnings Per Share

As for profitability, HOFSETH BIOCARE has a trailing twelve months EPS of kr-0.31.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -94.78%.

Volume

Today's last reported volume for HOFSETH BIOCARE is 184259 which is 31.16% below its average volume of 127327.

Moving Average

HOFSETH BIOCARE's value is higher than its 50-day moving average of kr2.89 and below its 200-day moving average of kr3.27.

More news about HOFSETH BIOCARE (HBC.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com